Oncometabolites from TCA Cycle Identified as Key Players in Tumor Growth and Immune Modulation

Researchers have identified oncometabolites derived from the tricarboxylic acid (TCA) cycle as significant factors in cancer progression and immune system interactions. A study led by Sarkar and colleagues highlights the role of these metabolic byproducts in influencing tumor behavior and modulating the surrounding immune microenvironment. The findings provide new insights into how metabolic pathways contribute to cancer biology.

The study focuses on specific metabolites produced during the TCA cycle, which is a central process in cellular energy production. These oncometabolites have been found to impact tumor growth and alter immune responses within the tumor microenvironment. By examining these interactions, researchers aim to better understand how cancer cells exploit normal metabolic processes to support their development and evade immune detection. The study emphasizes the importance of further investigating these mechanisms to uncover potential therapeutic targets for cancer treatment.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 30, 2025

Related posts:

HLS Therapeutics to Commercialize Cholesterol-Lowering Drugs Nexletol and Nexlizet in Canada Under Esperion Therapeutics Agreement ICH Q6B Provides Framework for Analytical Characterization of Biopharmaceuticals Amgen to Invest $600 Million in New Science and Innovation Center at US Headquarters Boston University Neurology Professor Receives Grant to Study Impact of Nursing Home Architecture on Resident Health

Author

GOAI